Compare Gilead Sciences, Inc. (GILD) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Workiva Inc — how do they compare? Gilead Sciences, Inc. trades at $133.04 (market cap $163.51B), while Workiva Inc trades at $56.26 (market cap $3.05B). The key difference: Gilead Sciences, Inc. is far larger — about 53.6× Workiva Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| GILD | WK | |
|---|---|---|
Market Cap | $163.51B | $3.05B |
Sector | Health | Technology |
52-Week High | $155.80 | $93.31 |
52-Week Low | $108.22 | $44.31 |
Enterprise Value | $178.05B | $2.98B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Workiva (WK) trades at $54.91, up 2.27% with strong technical momentum and bullish moving average signals. The company demonstrates robust revenue growth with Q1 2026 EPS beating estimates at $0.77 versus $0.66 expected, while maintaining a high gross margin of 79.4%. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and an $71 consensus price target, representing 29% upside potential from current levels.
WK offers compelling growth prospects with expanding profitability and dominant market positioning in compliance software, though elevated valuation multiples (P/E 226.58) and technical overbought conditions warrant caution. The stock faces execution risks in maintaining growth momentum amid competitive pressures, but strong institutional support and consistent earnings beats support the bullish outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
